![]() |
![]() |
![]() |
|||
|
|||||
PCI-24781![]() PCI-24781 is a broad-spectrum phenyl hydroxamic acid HDAC inhibitor currently being evaluated in phase I clinical trials in patients with neoplastic disease. The substance is a specific inhibitor of multiple HDAC isoforms (HDAC2, HDAC3/SMRT, HDAC6, HDAC8, HDAC10) that potently inhibits tumor growth in vivo with acceptable toxicity. Synonyms: CRA-02478; CRA024781; CRA-024781 Ordering Information: Product Number - EC-000.2348; Price and Availability: Inquire This product is also available to buy in bulk quantities. Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); APHA Compound 8; Droxinostat; SB939. References: ![]() |
|||||
Home
|
About Company
|
Contract Synthesis
|
Cheminformatics Services
|
Info for Chemists
|
Contacts
|
FAQ
|
Site Map © 2004-2016 Exclusive Chemistry Ltd. All rights reserved. |
|||||